AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 142 min read

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

Original reporting
finance.yahoo.com
Published Sep 14, 2026, 10:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 5:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

Med
01

Why it matters

The enforcement action adds regulatory risk to Doximity, likely prompting short‑term price weakness.

02

Market read

SEC judgment introduces new risk for Doximity, may affect investor sentiment and short‑term price action.

03

What to watch

Potential for the case to highlight broader insider‑trading risks in the sector, affecting peer valuations.

Relevance 8/10Novelty 8/10Timing: late last week

Background

SEC litigation release details the judgment against Doximity's ex‑CRO for insider trading based on nonpublic sales data.

Market effects

Sector

May raise compliance concerns for other health‑tech platforms and could prompt broader sector scrutiny.

Regional

U.S. market focus; limited regional spillover.

Global

Minimal global impact beyond U.S. health‑tech investors.

Counterpoint

What could challenge this read

The fine is relatively small for a listed company; long‑term fundamentals remain strong.

Key entities

  • Company
    Doximity

    Medical industry social networking platform (NASDAQ: DOX).

  • Individual
    Paul Jorgensen

    Former chief revenue officer of Doximity, convicted of insider trading.

Read at source← All news

Related articles

SEP 8
$DOCSMed

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

investing.com1 min
AUG 16
$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

aol.com6 min
AUG 14
$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.

fool.com7 min
AUG 11
$DOCSMed

Doximity Stock Surges in Overnight Trading as Chief Executive Highlights High-Margin AI Tool

Doximity (DOCS) shares jumped in overnight trading after CEO Jeffrey Tangney said the company’s new AI search tool generates over 10 times the revenue versus its operating cost. The stock later closed up 33% on Friday. Doximity reported Q1 revenue of $156.6M and adjusted EBITDA of $74.8M, and raised full-year guidance to $671M-$681M. Wells Fargo later downgraded to underweight.

tikr.com6 min
AUG 11
$DOCSMedAI 8/10

DOCS Q2 Deep Dive: AI Product Adoption Fuels Revenue Growth, Margins Face Investment Pressures

Doximity reported Q2 revenue of $156.6M, up 7.3% year over year and above analysts’ $151.3M estimate. Adjusted EBITDA was $74.77M versus $69.59M, but adjusted EPS was $0.29 versus $0.30. The company slightly lifted full-year revenue guidance to $676M midpoint, while EBITDA guidance of $319M trails estimates. Management cited AI product adoption and NOHARM study validation, alongside higher AI investment pressuring margins.

finance.yahoo.com7 min